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Estrogens are critical mediators of breast tumorigenesis. This occurs via the action of estrogens on the 
estrogen receptor (ER), which regulates the transcriptome of breast cancer cells. Despite the long history of the 
search for estrogen-regulated genes in breast cancer, knowledge of the E2-regulated transcriptome and its 
effects is incomplete. We used Affymetrix GeneChips to profile the effects of estradiol on the expression of genes 
in EFF-3, EFM-19 and MCF-7 cells. In addition to many well-characterized estrogen-regulated genes, this identified 
a novel group of genes that have roles in vesicle trafficking, including exocytosis. Recent evidence in the literature 
supports a role for vesicle trafficking in tumorigenesis. We focused on five genes (SYTL5, RAB27B, SNX24, 
GALNT4 and SLC12A2/NKCC1/BSC2) and confirmed their estrogen-regulation using quantitative real-time PCR 
(qPCR). qPCR also demonstrated that these five genes were expressed in invasive breast carcinoma tissue. 
Immunohistochemistry showed expression of SYTL5 in cells of normal breast ductal epithelium, ductal carcinoma 
in-situ (DCIS) and invasive breast carcinoma. The results suggest that a significant effect of estrogens is to 
regulate the expression of genes that affect diverse aspects of vesicle trafficking including exocytosis. 
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Estrogens are sex steroid hormones with a 
plethora of physiological and 
pathophysiological functions including a 
central role in the aetiopathogenesis of breast 
cancer. Estrogens alter gene expression in 
target cells via the nuclear-localized estrogen 
receptor (ER), which exists in two forms, ERƠ 
and ERơ [1]. 17ơ-estradiol (E2) has 
considerably greater biological activity than the 
other principal types of estrogens (estrone and 
estratriol) [2]. The estrogen-bound ER complex 
interacts with estrogen-responsive elements 
and with other transcription factors to regulate 
transcription of select genes, which in breast 
cancer cells, facilitate tumor development and 
progression [3-5]. 
 
One in ten women in Western society will 
develop breast cancer. There is epidemiologic, 
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clinical and laboratory evidence that estrogens 
have an important role in breast cancer 
pathology. Estrogens and estrogen antagonists 
have proliferative and antiproliferative effects, 
respectively on breast cancer cells [6, 7]. The 
successful use of systemic endocrine therapy 
drives the current interest in the 
pathophysiology of estrogens in breast cancer. 
Endocrine treatments include drugs which 
inhibit the production of estrogens such as the 
aromatase inhibitors, letrozole and 
anastrozole, or compete with estrogen for 
binding to the ER, such as the antiestrogens, 
tamoxifen and faslodex. Discerning the 
mechanisms of estrogen signaling, and the 
development of endocrine resistance will be 
instrumental in directing the future endocrine 
management of breast cancer. 
 
Since the advent of DNA microarray 
technology, a number of studies have been 
performed to identify E2-regulated genes in 
breast cancer cell lines building on our 
previous knowledge [8-16]. These studies 
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have contributed considerably to our 
knowledge and understanding of E2-regulated 
gene expression in breast cancer. These 
studies have tended to focus on three main 
areas: 1) cataloguing E2-regulated genes, 2) 
the mechanisms of ER-mediated gene 
regulation or 3) analysis of E2-regulated gene 
expression to predict of prognosis. Despite the 
large body of work performed, the majority of 
previous studies have been limited to one cell 
line only (MCF-7). In the present study, in 
addition to the most studied cell line, MCF-7, 
we have used two little studied cell lines (EFF-
3 and EFM-19) which have been grown in 
culture for relatively little time [17, 18]. 
Therefore, EFF-3 and EFM-19 cells are less 
likely to show a change the E2-regulated 
transcriptome from that of the original cells 
from which they are derived. Adding these two 
cell lines also addresses the issue of 
heterogeneity of the E2-regulated 
transcriptome that may exist between different 
cell lines. 
 
Vesicle trafficking is a constitutive and 
regulated process in eukaryotic cells, allowing 
essential cellular processes such as 
neurotransmission and hormone secretion 
[19]. One family of vesicle trafficking genes 
with over 60 members is the RAB GTPases, 
which have diverse roles including vesicle 
budding, tethering, fusion and transport, in 
addition to endocytosis and exocytosis [19]. 
There is now a growing body of evidence that 
strongly supports a role for vesicle trafficking 
and the genes that regulate this, in 
tumorigenesis [21-23]. 
 
In the present study, we tested the hypothesis 
that novel functional groups of E2-regulated 
genes exist. We report identification of a group 
of E2-regulated genes, which are implicated in 
different aspects of vesicle trafficking. This 
paper focuses on vesicle trafficking genes, as 
these represent a previously unrecognized 
group of E2-regulated genes and this may 
illuminate our understanding of the actions of 
E2 in breast cancer. 
 
 
Cell Lines, Culture Conditions and RNA 
Extraction 
 
E2-responsive ERƠ+ (EFF-3, EFM-19, MCF-7) 
and E2-independent ERƠ- (MDA-MB-231, 
Hs578T, SK-BR-3) human breast cancer cells 
were cultured in Dulbeccos modified Eagles 
medium (DMEM) containing 10% fetal calf 
serum and 1 ƫg/ml insulin. Cells were grown 
to approximately 70% confluence in T25 or 
T75 flasks. Experiments were performed in 
triplicate for each cell line. Withdrawal from 
steroids present in the routine culture medium 
involved culture for 7 days in phenol red-free 
DMEM containing 10% newborn calf serum 
(treated with dextran-coated charcoal) and 1 
ƫg/ml insulin. During the first 3 days of steroid 
withdrawal, cells were washed with PBS twice 
prior to replenishment with steroid depleted 
medium. Cells were then cultured in either 
steroid depleted medium or in depleted 
medium containing 10-9M E2 for 48 hr. 
Medium was changed daily. 
 
E2-dose response and time course 
experiments were performed with MCF-7 cells 
under the same conditions as described 
above. E2-dose response experiments were 
performed in the presence of 0  10-7M E2 for 
48 hours. Time course experiments were 
performed under conditions of steroid-
withdrawal or in the presence of 10-9M E2 for 
0  96 hours. Total RNA was extracted using 
TRIZOL reagent (Invitrogen Life Technologies, 
Inc., Invitrogen Corp., Carlsbad, CA). 
 
Breast Tumors and RNA Extraction 
 
Ethical permission was obtained from the 
Local Research Ethics Committee. Invasive 
breast carcinoma of no special type (NST) 
samples (n=18) were macro-dissected by a 
histopathologist from surgical specimens at 
the Royal Victoria Infirmary, Newcastle upon 
Tyne. Samples were pulverized at liquid 
nitrogen temperature using a tungsten carbide 
ball in a tissue dismembrator and RNA purified 
following LiCl/urea precipitation [21, 22]. As 
ERƠ status was unknown and paraffin blocks 
were unavailable, owing to the small quantity 
of sample material, qPCR was used to 
determine ERƠ mRNA expression. Tumors 
were divided into two groups (ERƠ+ and ERƠ-) 
based on ERƠ expression. The mRNA 
expression of the five vesicle trafficking genes 
(described below) was compared between the 
two groups using the Mann-Whitney test 
(Minitab software). 
 
RNA Assessment 
 
All RNA samples were assessed for quality by 
spectrophotometry and agarose gel 
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electrophoresis. Additionally, RNA samples for 
Affymetrix GeneChip hybridization were 
purified on Rneasy mini-columns according to 
the manufacturers instructions (Qiagen) and 
were also assessed by Affymetrix test chips 
(Affymetrix, Inc., Santa Clara, CA). 
 
GeneChip Microarrays 
 
Labeled cRNA was prepared following 
Affymetrix protocols (www.affymetrix.com). 
Double-stranded cDNA was synthesized from 5 
µg total RNA using a T7-(dT)24 primer 
(Invitrogen). cRNA was then synthesized by in 
vitro transcription and biotinylated using the 
Bioarray High-Yield RNA Transcript Labeling kit 
(Affymetrix). Labeled targets (20 µg/sample) 
were fragmented and hybridized to Hu U133 
Plus 2.0 GeneChips in a rotating oven at 45ºC 
at the Microarray Facility, University of 
Newcastle. GeneChips were washed and 
stained with streptavidin-conjugated 
phycoerythrin on a fluidics station and 
scanned twice at 570 nm in a GeneArray 
Scanner at a resolution of 3 µm. Data was 
analyzed with MicroArray Suite 5.0 software 
(Affymetrix). Default settings for absent and 
present calls were p < 0.04 (present), p 0.04  
0.06 (marginal) and p > 0.06 (absent). Global 
scaling normalization was used to normalize 
the expression data to the target value of 150. 
Gene expression was deemed to be regulated 
if the signal in the samples differed two-fold 
(signal log ratio >1.0 or <-
1.0; http://www.netaffx.com). It is not possible 
to know the exact fold-change that represents 
a significant regulation of gene expression 
(and this may be different for individual 
genes). A two-fold cut-off was selected, as this 
is commonly accepted as appropriate in other 
microarray studies. 
 
Quantitative Real-time PCR (qPCR) 
Primers were designed using Primer Express 
software (Applied Biosystems) so that the 
amplicon crossed intronexon boundaries 
( ). A nucleotide BLAST search was 
performed to ensure that primers were specific 
for the intended transcripts 
(http://www.ncbi.nlm.nih.gov/blast/). For 
reverse transcription, 1.0 ƫg of DNase treated 
RNA was incubated in 50 mM Tris HCl pH 8.3, 
79 mM KCl, 3 mM MgCl2, 10 mM DTT, 2 mM 
dNTPs, with 0.5 ƫM oligo dT12-18 (Amersham) 
and 60 U Moloney murine leukemia virus 
reverse transcriptase (USB) in 20 ƫL for 1 hr at 
37ºC. qPCR reactions contained 120 nM 
primers in 0.33 ƫL of the reverse transcription 
reaction with a final volume of 10 ƫL using 
SYBR Green JumpStart Taq (Sigma) as 
recommended by the manufacturer. Each 
sample was loaded in triplicate onto an ABI 
Prism 7900HT Sequence Detection System 
(Applied Biosystems). Data was analyzed using 
SDS 2.2 software to assess the level of 
expression of target genes using the absolute 
quantification method involving generation of 
a standard curve for each gene (ABI Prism 
7900HT Sequence Detection System and SDS 
Enterprise Database) 
(http://www.appliedbiosystems.com). The 
maximum fluorescence for each gene was 
normalized for ơ-actin expression. 
 
Western Blot Analysis 
 
MCF-7 and Hs-578T cells grown in the 
presence of 10-9M E2 were lysed using RIPA 
buffer and proteins prepared for Western blot 
analysis. 5µg protein samples were subjects to 
SDS-PAGE and proteins transferred to 
nitrocellulose membranes. The membranes 
were incubated with anti-SYTL5 antibodies 
(raised by PickCell Laboratories) overnight at 
4ºC followed by horseradish peroxidase 
conjugated goat anti-rabbit antibody at 
 
 
 Primer sequences and correlation coefficients (R2) for qPCR reactions 
Gene Forward primer Reverse Primer 
Correlation 
coefficients (R2) 
GALNT4 GGCCTATATCTTCGTGGAGCTC CCTGCGGAGGCATGAAAA 0.9766 
RAB27B GTGCATCTTCAGCTTTGGGAC GAGACTCCGGAACCGCTCTT 0.9935 
SLC12A2 ATCAATTTTTCAGTATTCCATGCATC ACGCCATCCTGGAGATTTTG 0.9995 
SNX24 TCAAGCAAACTGTCCCACCA ATATGGATCCCTGAGGAACAGC 0.9965 
SYTL5 GCCCCAATGGCAGCTG TTAGCTGCGCGATTTTGTCAC 0.9866 
TFF1 CCCAGACAGAGACGTGTACAGTG AACCACAATTCTGTCTTTCACGG 0.9989 
ơ-actin GGTCATCACCATTGGCAATG CCACAGGACTCCATGCCC 0.9992 
RERG ACCAAACGGTTCATCTGGGA TCGGTAGGTTGATTCGAGGGT 0.9990 
ER Ơ GCTCTTGGACAGGAACCAGG AAGATCTCCACCATGCCCTCT 0.9843 
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 qPCR demonstrating the mRNA expression of TFF1 in EFF-3, EFM-19, MCF-7, MDA-MB-231, Hs578T and 
SK-BR-3 cells after 48 hours E2-stimulation (E2) compared with steroid withdrawn (CONT) samples. (Error bars 
are standard deviation of three independent replicates.) 
 
 
1:2000 in PBST/5% non-fat milk for 1 hour at 
370C (Pierce). Filters were visualized using 
chemiluminescence (Super-Signal West Dura 
Extended Duration Substrate Kit). 
 
Immunohistochemistry 
 
Ethical approval was obtained from the local 
research ethics committee. Formalin-fixed 
paraffin-embedded tissue was used from 
breast reductions (n=2), ductal carcinoma in 
situ (DCIS) (n=6) and invasive breast 
carcinomas (n=13) (invasive ductal carcinoma 
NST [n=9], mucinous carcinoma [n=3]) ([ERƠ+: 
n=6] [ERƠ: n=7)). ERƠ-status of invasive 
breast carcinomas had previously been 
determined during routine clinical 
histopathological diagnosis by 
immunohistochemistry according to national 
guidelines (The Royal College of Pathologists, 
UK). 4 µm sections were cut using a 
microtome and deparaffinized for 10 minutes 
in xylene, followed by 2 99% IMS rinses and 
then taken down to water. Sections were 
subject to a 2 hr pressure cooker treatment 
(20 minutes at pressure and left to stand for 
the remaining time) in pH9 retrieval solution 
(Novocastra). The sections were then loaded 
onto the Dako Techmate 500 automated 
stainer. After washing in Buffer (Dako), they 
are incubated for 10 minute 3% H202 in 
methanol endogenous peroxidase block. After 
rinsing the sections were incubated for 10 
minutes in Normal Goat Serum block. Then 
sections were incubated for 1 hour at room 
temperature with anti-SYTL5 antibody (1:500) 
(PickCell Laboratories) diluted in PBS. After 
incubation with primary antibody, sections 
were rinsed twice and then incubated for 30 
minutes with undiluted Envision visualization 
reagent (Dako). Following further washes the 
sections are incubated with Dako Envision 
chromogen at 1:50 dilution for 18 minutes at 
room temperature. Finally sections are 
incubated with 5% copper sulphate solution to 
enhance staining and counterstained with 
hematoxylin. Then sections were rinsed in 
water, dehydrated through graded alcohol and 
xylene, and mounted in DePeX (BDH). Negative 
controls were performed by omission of the 
primary antibody and incubation with PBS. 
 
 
Validation of the Transcriptome Effects of E2 
Stimulation and Steroid Withdrawal on Breast 
Cancer Cell Lines 
 
qPCR for the established E2-regulated gene, 
TFF1, was performed on all cell line RNA 
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samples [16]. This confirmed that E2 
stimulated a strong induction of TFF1 mRNA 
expression in E2-responsive ERƠ+ cell lines 
(EFF-3, EFM-19 & MCF-7) at 48hr time points 
( ), and in E2 dose-response and time 
course experiments (MCF-7). TFF1 mRNA was 
either not expressed or was expressed at lower 
levels in E2-independent ERƠ- cell lines (MDA 
MB-231, Hs578T & SK-BR-3) and showed no 
change in expression with E2-stimulation 
( ). The demonstration of these 
patterns of mRNA expression for the axiomatic 
E2-regulated gene, TFF1, confirms that 
experimental conditions including steroid 
withdrawal and E2-stimulation were 
appropriate. 
 
GeneChip Microarray Analysis of EFF-3, EFM-
19 and MCF-7 Cell Lines 
 
qPCR was performed on RNA samples used for 
microarray studies to determine mRNA 
expression of TFF1, RERG, SYTL5, RAB27B, 
SLC12A2, SNX24 and GALNT4. This 
demonstrated a strong correlation between 
microarray data and qPCR, including the 
direction of regulation (induction or repression) 
and the degree of regulation (
;  1,  and ). 
 
255, 748 and 2077 transcripts in EFF-3, EFM-
19 and MCF-7 cells respectively, showed 2-
fold regulation of expression by E2. Numerous 
established E2-regulated genes were 
identified, including PgR, TFF1, PDZK1, 
GREB1, IRS1, IGF1R, CDC2, CDC6, IGFBP4, 
RERG, STC2, CXCL12 and BLNK. The 
identification of known E2-regulated genes 
further validates the experimental conditions 
and the microarray data. 
 
We believed that while existing gene ontology 
systems have significant value to help 
elucidate the functional significance of 
microarray data, that they also have 
limitations. Therefore, in order to avoid 
classifying genes in a pre-defined manner or 
focusing on gene networks, a literature search 
was performed for all characterized genes 
detected by the arrays (www.pubmed.com). 
The most notable finding was the unexpected 
identification of 147 genes implicated in 
various aspects of membrane, protein and 
vesicle trafficking, including exocytosis 
( ). Instead of cataloging 
all E2-regulated genes or studying mechanistic 
aspects of ER function, we wished to focus on 
a novel group of yet unrecognized E2-regulated 
genes: vesicle trafficking genes. 
 
Varying patterns of induction and repression of 
expression of vesicle trafficking genes were 
seen in EFF-3, EFM-19 and MCF-7 cells with 
the majority being regulated in one or two out 
of the three cell lines. Based on a 2-fold cut-
off, only eight vesicle trafficking genes showed 
regulation in all three cell lines (GALNT4, 
PDZK1, PPFIA4, RAB27B, RERG, SLC12A2, 
SNX24 and SYTL5). All of these genes were up-
regulated except SLC12A2 and RAB27B, 
which were down-regulated. RERG and PDZK1 
are known E2-regulated genes that have 
already been studied in breast cancer [13]. 
One striking finding was the identification of a 
large number of RAB GTPases, RAB-
like/related genes and Rho-related genes. 
Many of the genes identified are implicated or 
known to have roles in exocytosis, including 
RAB GTPases, SNAP23, SLC12A2, STX16, 
RIMS3, SYTL4, SYTL5, VAMP2 and VAMP8 
( ). 
 
E2 Regulation and Expression of 5 Vesicle 
Trafficking Genes in Breast Cancer Cell Lines 
 
We selected five vesicle trafficking genes 
(SYTL5, RAB27B, SNX24, GALNT4 and 
SLC12A2), which were consistently E2-
regulated in EFF-3 EFM-19, and MCF-7 cells 
for further investigation. qPCR was performed 
with all 6 cell lines used in the study with 
steroid withdrawn and E2-stimulated samples 
at 48 hour time points. This confirmed that all 
five genes showed a strong pattern of E2-
regulation of mRNA expression in EFF-3, EFM-
19 and MCF-7 cells, which was 2-fold in all 
cases with the same direction of regulation 
(induction or repression) as predicted by 
microarray data ( ). SNX24 and 
RAB27B showed a similar degree of relative 
regulation with microarray analysis and qPCR. 
The other genes showed more variation 
between cell lines. However, despite the 
accuracy of Affymetrix GeneChips, in the 
current setting, their principal role is as a 
genome-wide screening method, rather than 
as a tool for precise quantification of 
expression of individual genes. Therefore, 
exact correlation of the degree of regulation 
between the two methods cannot be expected. 
 
Whereas all five genes showed a consistent 
pattern of E2-regulation in all three ERƠ+ cell 
lines, these genes showed no evidence of 
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 qPCR demonstrating E2-regulation of SYTL5, GALNT4, SNX24, RAB27B and SLC12A2.  E2-regulation 
of all 5 genes in EFF-3, EFM-19 and MCF-7 cells showing mRNA fold change after 48 hours E2-treatment. The 
effects of E2-stimulation for 48 hours on SYTL5 mRNA expression on 6 breast cancer cell lines comparing steroid 
withdrawn (CONT) with E2-stimulated (E2) samples. SYTL5 mRNA expression in MCF-7 cells after E2-
stimulation for 0 to 96 hours, comparing steroid withdrawn (CONT) with E2-stimulated (E2) samples.  SYTL5 
mRNA expression in MCF-7 cells after 48 hours in the presence of 0  10-7M E2. (Error bars are standard 
deviation of three independent replicates.) 
 
 
regulation in the three ERƠ- cell lines. 
Furthermore, all five genes were generally 
either not expressed or expressed at much 
lower levels in the ERƠ- cell lines. These 
findings are concordant with what is expected 
and support their existence as E2-regulated 
genes. Data is further illustrated for one gene, 
SYTL5 in  recapitulating what has 
been described but showing the relative level 
of mRNA in control and E2-treated samples. 
 shows that EFF-3, EFM-19 and MCF-
7 cells demonstrated a strong induction of 
expression after 48 hours of E2-stimulation. It 
also confirms the lack of regulation in MDA-
MB-231, Hs-578T and SK-BR-3 cells. SYTL5 
was expressed at very low or insignificant 
levels in MDA-MB-231 and Hs-578T cells. 
However, it was expressed at comparable but 
slightly lower levels in SK-BR-3 cells than in the 
E2-treated samples of EFF-3 and EFM-19 cells. 
EFM-19 cells showed the greatest degree of 
E2-regulation (17.96-fold), compared with EFF-
3 and MCF-7 cells ( ). Despite this, 
EFM-19 cells had the lowest levels of SYTL5 
expression after E2-stimulation compared with 
EFF-3 and MCF-7 cells ( ). MCF-7 cells 
showed the highest level of SYTL5 expression 
after E2-stimulation despite having a lower 
fold change in expression (  and ). 
 
Time course and E2 dose-response 
experiments with MCF-7 cells demonstrated 
that all five genes showed a strong pattern of 
induction (GALNT4, SNX24 and SYTL5) or 
repression (RAB27B and SLC12A2) of mRNA 
expression by E2. Corresponding control 
samples showed relatively lower (GALNT4, 
SNX24 and SYTL5) or higher (RAB27B and 
SLC12A2) expression levels than E2-treated 
samples. All five genes showed rapid E2-
regulation of expression within 6 hours, which 
was maintained up to 72 hours (RAB27B and 
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GALNT4) or 96 hours (SYTL5, SNX24 and 
SLC12A2). The time to reach the maximum 
(SYTL5, SNX24 and GALNT4) or minimum 
(RAB27B and SLC12A2) expression level was 
6 hours (SYTL5), 12 hours (SNX24 and 
RAB27B), 48 hours (GALNT4) and 72 hours 
(SLC12A2). All five genes showed a pattern of 
expression reflecting a pharmacological E2 
dose-response effect with maximum regulation 
between 10-10M and 10-7M.  and  
illustrate time course and E2 dose-response 
data respectively for SYTL5. SYTL5 showed a 
rapid and maximal induction at 6 hours, which 
was persistent over time but showed a lower 
level of induction at 72 and 96 hours.  
 shows E2-regulation of SYTL5 expression 
with a characteristic sinusoidal dose-response 
curve with maximal regulation at 10-9M, a dose 
that is considered to be near physiological [6, 
14, 15]. Together these data support the 
mRNA expression of all five genes being under 
the regulation of E2. The early induction of 
these genes and the E2 dose-response 
patterns suggest that these genes are 
regulated directed by E2 rather than via 
secondary effects of other E2-regulated 
translated proteins. 
 
mRNA Expression of 5 Vesicle Trafficking 
Genes in Invasive Breast Carcinoma 
 
Concentrations of ERƠ mRNA varied over 700 
fold. Six tumour samples had a low expression 
of ERƠ, similar to the levels in the ERƠ- breast 
cancer cell lines, and were designated ERƠ-. 
The remaining tumours expressed ERƠ at 
levels equivalent to or greater than those in 
the ERƠ+ breast cancer cell lines and were 
designated ERƠ+.  illustrates the 
mRNA expression levels in relative units for the 
five vesicle trafficking genes (GALNT4, SNX24, 
SYTL5, RAB27B and SLC12A2) in 18 breast 
tumours. All five genes were expressed in 
breast tumours, each gene showing varying 
patterns of expression. The mean level of 
expression was higher for each gene in the 
ERƠ+ tumours than the ERƠ- tumours. 
However, this did not reach statistical 
significance with SNX24 having the lowest p-
value (p=0.0593). As association of E2-
regulated genes with ERƠ-status was not the 
focus of this study, this was not further 
investigated. 
 
Protein Expression of SYTL5 in Breast Tumors 
 
One vesicle trafficking gene, SYTL5, was 
selected for investigation of protein expression 
in breast tumours. Anti-SYTL5 polyclonal rabbit 
antibody was validated by performing Western 
blotting with protein extracts from breast 
cancer cell lines. Strong immunoreactive 
bands were identified in MCF-7 corresponding 
to proteins at 70KDa, 50KDa and 45KDa after 
20 minutes exposure ( ). Although 
SYTL5 is predicted to encode an 81.52KDa 
protein, this is the first study of SYTL5 protein 
in human tissues. Exact correlations between 
predicted and actual molecular weights are 
not unexpected. No bands were identified with 
the Hs-578T protein. SYTL5 protein and mRNA 
expression correlate strongly, both being 
expressed at high levels in MCF-7 cells but 
absent or at very low levels in Hs-578T cells 
(  and ). 
 
Immunohistochemistry controls with no 
primary antibody showed no staining in all 
tissue samples used including normal breast 
tissue and invasive breast carcinoma 
specimens. There was moderate to strong 
immunostaining for SYTL5 within the ductal 
epithelial cells and within the lumina of breast 
ducts of normal breast tissue ( ). 
 
There was moderate SYTL5 immunostaining in 
three DCIS samples and strong staining in 
 
 
 
 
 
 mRNA expression of SYTL5, GALNT4, 
SNX24, RAB27B and SLC12A2 in invasive breast 
carcinoma tissue samples and MCF-7 cells. (ɿ ERƠ+ 
tumors,  ɾ ERƠ- tumors,   mean mRNA expression, 
X MCF-7 cells. Y-axis: mRNA expression in relative 
units.) 
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  SYTL5 protein expression in breast cancer. SYTL5 protein expression determined by Western blotting 
in MCF-7 and Hs578T cells.  Immunohistochemistry showing SYTL5 protein expression in normal breast 
tissue (strong staining) (B), DCIS (strong staining) (C), ER- invasive breast carcinoma NST (moderate staining) (D) 
and ER+ invasive breast carcinoma NST (strong staining) (E and F). (Scale bar = 100ƫm) 
 
 
the remaining three DCIS samples ( ). 
The majority or all DCIS cells stained in five 
samples and moderate numbers of DCIS cells 
stained in one sample. All 13 invasive breast 
carcinomas showed SYTL5 immunostaining of 
carcinoma cells with strong staining in eight 
tumours and moderate staining in five tumours 
( ). No difference in intensity of 
immunostaining was detected between ERƠ+ 
and ERƠ- tumours. Ten tumours showed 
staining of the majority or all carcinoma cells 
and three tumours showed staining of 
moderate numbers of carcinoma cells. 
Staining was present in a diffuse fine granular 
cytoplasmic pattern in carcinoma cells (
). Nuclear or cell membrane staining was 
not apparent. The extracellular matrix did not 
stain. With the exception of occasional cells, 
stromal fibroblasts did not stain. Adipocytes 
and vascular smooth muscle cells showed no 
immunostaining. The pattern of 
immunostaining in these samples including 
the lack of staining in the negative control and 
in non-cancer cells suggests that the staining 
was not non-specific, and that SYTL5 protein is 
expressed in breast cancer. 
 
 
Identification of E2-regulated Vesicle 
Trafficking Genes in Breast Cancer 
 
In the present study we report 147 vesicle 
trafficking genes that showed E2-regulation of 
mRNA expression in breast cancer cells. Five 
of these (SYTL5, RAB27B, SNX24, GALNT4 
and SLC12A2) have been validated in detail 
using qPCR and showed a consistent pattern 
of E2-regulation in EFF-3, EFM-19 and MCF-7 
cells. These five genes were also expressed as 
mRNA in invasive breast carcinoma tissues. 
SYTL5 protein was expressed in MCF-7 cells 
but not in Hs578T cells. SYTL5 protein was 
also expressed in benign breast ductal 
epithelial cells and in breast carcinoma cells 
(DCIS and invasive carcinoma). SYTL5 was 
expressed with a fine granular cytoplasmic 
pattern suggesting that it may be localized to 
vesicles on the micron or submicron scale. 
Although there was a pattern of higher SYTL5 
mRNA expression in ERƠ+ than ERƠ- cell lines, 
there was no statistically significant 
association with ERƠ status of primary tumors. 
SYTL5 protein expression also showed no clear 
association with ERƠ status. This may be 
explained in part by sample size. Also, it 
should be considered that this finding is not 
necessarily unexpected as E2-regulated genes 
and ERƠ-associated genes are not 
synonymous [13]. 
 
Varying patterns of E2-regulation of vesicle 
trafficking genes were detected between cell 
lines. The majority of genes only showed E2-
regulation in one or two of the three cell lines 
and a few, for example RAB31, showed bi-
470  Int J Clin Exp Pathol (2009) 2, 463-475 
Wright PK et al/Estrogen Regulation of Vesicle Trafficking Genes in Breast Cancer 
directional E2-regulation between cell lines. 
Only eight genes were consistently E2-
regulated in all three cell lines, five of which 
we have studied in detail. 
 
These findings are in keeping with the current 
knowledge of E2-regulated genes in breast 
cancer [13]. It is incorrect to assume that the 
E2-regulated transcriptome of MCF-7 cells is 
identical to that of other breast cancer cells, 
both in culture and in vivo. It is well known that 
there is considerable heterogeneity of gene 
expression between different tumors and 
between different cancer cell lines [24]. 
Previous work has shown that only a minority 
of E2-regulated genes are common to different 
cell lines. Rae et al only reported three such 
genes out of 811 that were common to three 
breast cancer cell lines [10]. Soulez and 
Parker identified cytochrome P450 IIB as the 
most up-regulated (>100 fold) gene by E2 in 
ZR75-1 cells, and also reported that it was 
neither expressed nor E2-regulated in MCF-7 
cells [9]. The reader should also consider that 
ERƠ itself is an E2-regulated gene that is bi-
directionally regulated between different cell 
lines [25]. All of this points towards there 
being considerable heterogeneity of the E2-
regulated transcriptome in breast cancer. 
 
There are a number of possible reasons why 
previous authors have not given full 
recognition to vesicle trafficking genes. These 
include the tendency to limit studies to one 
cell line, gene ontology classification systems, 
a focus on genes with the greatest degree of 
regulation or a focus on the predictive value of 
gene signatures rather than gene function [11-
13]. There has also often been a focus on E2-
regulation of genes that regulate the cell cycle 
with less recognition being given to other E2-
regulated genes [4]. 
 
Although the present study describes a novel 
group of E2-regulated genes in breast cancer, 
these findings are not entirely unexpected 
when the wider literature is considered. E2 has 
been shown to regulate the expression of six 
proteins involved in exocytosis in the rat 
pituitary gland (synaptotagmin 1, syntaxin 1, 
RAB3A, SNAP25, synaptobrevin 2 and 
cellubrevin) [26]. E2 also regulates the 
expression of RAB11 in endometrial cells, 
which also correlates with our findings [27]. 
RAB31 and RAB5C-like expression has 
previously been reported to be E2-regulated in 
MCF-7 and ZR75-1 cells respectively [8, 9]. 
However, little recognition has been given to 
the significance of their function. In 1982, Vic 
et al studied the effects of E2 on the 
ultrastructure of MCF-7 cells and reported that 
E2 lead to formation of small intracellular 
vesicles, which were released into the 
extracellular fluid by an exocytosis-like process 
[28]. However, the significance of these 
electron microscopy results has been given 
very little subsequent recognition or 
investigated further. There are significant 
parallels between the morphology described 
by Vic et al and the gene expression findings of 
the present study. 
 
SYTL5, RAB27B, SNX24, GALNT4 and 
SLC12A2 
 
Synaptotagmin-like 5 protein (SYTL5) is a 
novel 730 amino acid E2regulated protein 
[29]. It belongs to a group of proteins thought 
to be involved in vesicle trafficking and 
exocytosis. Synaptotagmin-like proteins are 
mediators of neurotransmitter release and 
have a role in hormone release from endocrine 
cells. SYTL5 and SYTL4 (which was also 
identified as E2-regulated) are effector 
molecules that specifically bind and regulate 
the GTP-bound form of the GTPase RAB27A/B 
[29, 30]. In this regard, the concurrent 
identification of SYTL5 and its hypothetical 
partner molecule RAB27B may be significant. 
Interestingly, SYTL1 and RAB27A are known 
vesicle trafficking partner molecules in 
androgen-regulated secretion of prostate-
specific antigen (PSA) and prostatic-specific 
acid phosphatase (PSAP) in prostate cancer 
cells [31]. 
 
Ras-related protein RAB27B (RAB27B) is a 
218 amino acid membrane-bound member of 
the Ras oncogene family of GTPases. RAB27A 
and RAB27B are closely related GTPases 
involved in vesicle trafficking and exocytosis 
[30, 32]. RAB27B is involved in melanosome 
trafficking, and exocytosis of hormones, 
enzymes and platelet dense core granules. 
RAB27A is implicated in lymph node 
metastasis in murine xenograft breast cancer 
models [33]. 
 
Sorting nexin 24 (SNX24) is a little studied PX 
domain-containing vesicle trafficking protein of 
199 amino acids. Sorting nexins form a 
diverse family, some of which are known to be 
regulators of endosomal sorting [34]. This 
includes protein and membrane trafficking 
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between the sorting endosome compartment 
and the cell membrane, the Golgi body and 
lysosomes. Although there is evidence that 
SNX1, SNX2, SNX10 and SNX16 are involved 
in tumorigenesis, SNX24 remains 
uninvestigated [33, 35-38]. 
 
U D P -N - ac e ty l - a l p h a - D -ga l a c t o s amin e :
polypeptide N acetylgalactosaminyl-
transferase 4 (GALNT4) is a 578 amino acid 
type II membrane protein that catalyzes the 
initial reaction in O-linked oligosaccharide 
biosynthesis, the transfer of an N-acetyl-D-
galactosamine residue to a serine or threonine 
residue on the protein [39]. It is located in the 
Golgi body where it forms part of the protein 
and vesicle trafficking pathway. 
 
Solute carrier family 12 (sodium/ 
potassium/chloride transporters) member 2 
(SLC12A2/NKCC1/BSC2) is a bumetanide-
sensitive 1,191 amino acid integral membrane 
protein that is expressed ubiquitously, in 
particular, in the basolateral membrane of 
epithelial cells and in the nervous system. It is 
an electroneutral cation-chloride cotransporter 
that mediates sodium and chloride 
reabsorption and plays a vital role in the 
regulation of ionic balance and cell volume 
[40]. It mediates exocytosis of catecholamines 
from chromaffin cells and is involved in 
neuroregulation and breast morphogenesis 
[41, 42]. 
 
The Significance of E2-regulated Vesicle 
Trafficking Genes in Breast Tumorigenesis 
 
In 2002, Palmer et al reported that a chimeric 
transcription factor (EWS-WT1), a fusion 
product of chromosomal translocation in 
desmoplastic small round cell tumor, led to a 
large induction of BAIAP3, a protein involved in 
exocytosis. This introduced what appeared to 
be a new paradigm of exocytosis-mediated 
tumorigenesis [21, 22]. 
 
There is now a large body of evidence that 
vesicle trafficking and exocytosis are important 
in tumorigenesis [21-23]. A growing number of 
vesicle trafficking genes have been shown to 
have roles in tumourigenesis or are over-
expressed in diverse types of cancer [23]. This 
includes at least 21 RAB GTPases, 
synaptotagmin I, syntaxins, septins, TPD52, 
SNAP25, sorting nexins, LIMK1, RAC1, RAP1A 
and REBL1 [23, 35-38, 43-47]. 
Cheng et al showed that of the genes in the 
region of the 1q22 amplification in ovarian 
and breast cancers, RAB25 was over-
expressed [48, 49]. Increased RAB25 
expression increased tumourigenesis in vitro 
and in vivo. In murine xenograft breast and 
ovarian cancer models, RAB25 over-
expression increased tumour cell growth and 
worsened prognosis, whereas reduced RAB25 
expression decreased tumour proliferation. 
More recently, Hou et al showed that RAB23 is 
an amplified over-expressed gene in gastric 
cancer that has an important role in invasion 
[50]. 
 
The work of Montel et al has highlighted that a 
significant number of metastasis-associated 
genes in their study had vesicle trafficking 
roles [33, 51]. These included RAB27A, 
RAB38, SNX10, syntaxin 7, SNAP23 and 
VAMP-A, which were differentially expressed in 
murine xenograft models of breast cancer 
metastasis. 
 
Extracellular microvesicles are <1ƫm diameter 
vesicles that are released from normal and 
cancer cells into the extracellular fluid [52, 53, 
54]. Microvesicles (MV) are considered to be 
ectoorganelles with cell to cell communication 
roles including via growth factors, and 
horizontal transfer of receptors (e.g. CXCR4) 
and mRNA (e.g. VEGF, MMPs) between cells 
[55, 56]. They are formed within and released 
from cells by intracellular vesicle trafficking, 
although these pathways are largely 
unstudied. MV have been purified from cancer 
cell lines and malignant effusions [57]. They 
are well studied and there is strong evidence 
that they have important roles in diverse areas 
of tumourigenesis. This includes tumor 
invasion, growth factor release, angiogenesis, 
the p53 response, tumor immune privilege, 
neoplastic coagulopathy and chemotherapy 
resistance [58-64]. MV have been shown to 
contain proteins (e.g. VEGF, MMPs, FGF, tissue 
factor, CXCR4 & HER2), DNA, mRNA, 
microRNAs and even mitochondria [23, 52, 
53, 55, 57]. 
 
The exact roles and interactions of the large 
number of E2-regulated vesicle trafficking 
genes in breast cancer remain unclear. 
However, by identifying this novel group of 
genes, it is hoped that this will broaden our 
perspective and understanding of breast 
cancer. Previous authors have already shown 
that some of these genes or other members of 
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the same gene family are involved in 
tumourigenesis. Future work is now required to 
elucidate the roles of vesicle trafficking in 
breast cancer and to integrate it with our 
current knowledge. Furthermore, the function 
of individual genes requires characterization in 
relation to the exocytosis-like process 
described by Vic et al, which has now been re-
discovered over a quarter of a century later 
[28]. 
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